We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avanos (AVNS) Earnings and Revenues Beat Estimates in Q4
Read MoreHide Full Article
Avanos Medical, Inc. (AVNS - Free Report) reported adjusted earnings per share (EPS) of 34 cents in fourth-quarter 2019, which surpassed the Zacks Consensus Estimate of 32 cents. The bottom line rose by a penny year over year.
For 2019, EPS was $1.07, up 30.5% from the 2018 figure.
Revenues of this Zacks Rank #4 (Sell) company were $189.8 million which beat the Zacks Consensus Estimate by 6.7%. Also, the figure improved 11.7% on a year-over-year basis.
Full-year revenues totaled $697.6 million, up 6.9%.
Q4 Segmental Analysis
Chronic Care
Net revenues at this segment of $113.4 million rose 15.5% year over year.
Pain Management
The segment reported net revenues of $76.4 million. The metric improved 6.6% on a year-over-year basis.
AVANOS MEDICAL, INC. Price, Consensus and EPS Surprise
Gross profit came in at $109.7 million, up 9.3% from the prior-year quarter figure. Adjusted gross margin was 60% of net revenues, down 40 bps year over year.
Research and development expenses totaled $8.4 million, down 20.8% year over year. Selling, general and administrative expenses amounted to $103.6 million, up 17.9%.
Adjusted operating profit in the fourth quarter was $26 million, up 30% driven by higher sales volumes. The company reported operating loss of $3.2 million in the quarter under review compared with the year-ago quarter’s operating loss of $8.3 million.
Financial Update
As of Dec 31, 2019, cash and cash equivalents totaled $205.3 million.
Net cash from operating activities for the three months ended Dec 31, 2019, amounted to ($2.9) million, narrower than ($7.4 million) in the prior-year quarter.
Guidance
Avanos expects 2020 revenue growth between 5% and 7% compared to 2019. The Zacks Consensus Estimate for the same is pegged at $737.6 million.
Adjusted EPS is expected between a penny and $1.20. The Zacks Consensus Estimate stands at $1.18.
The company expects lower foreign currency impact in 2020 in comparison to 2019.
Summing Up
Avanos exited the fourth quarter on a strong note. The company continues to gain from core segments — Chronic Care and Pain Management. The recent FDA approval for the new 80-Watt COOLIEF Radiofrequency System buoys optimism. Also, the company completed the Endoclear LLC buyout and also entered into an operating partnership with DHL Supply Chain to enhance Avanos’ network achieve greater productivity and maximize warehouse storage utilization.
However, the contraction in gross margin is worrisome. Moreover, being a pure-play MedTech company, it faces stiff competition from other industry players.
Stryker reported fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the consensus mark by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Avanos (AVNS) Earnings and Revenues Beat Estimates in Q4
Avanos Medical, Inc. (AVNS - Free Report) reported adjusted earnings per share (EPS) of 34 cents in fourth-quarter 2019, which surpassed the Zacks Consensus Estimate of 32 cents. The bottom line rose by a penny year over year.
For 2019, EPS was $1.07, up 30.5% from the 2018 figure.
Revenues of this Zacks Rank #4 (Sell) company were $189.8 million which beat the Zacks Consensus Estimate by 6.7%. Also, the figure improved 11.7% on a year-over-year basis.
Full-year revenues totaled $697.6 million, up 6.9%.
Q4 Segmental Analysis
Chronic Care
Net revenues at this segment of $113.4 million rose 15.5% year over year.
Pain Management
The segment reported net revenues of $76.4 million. The metric improved 6.6% on a year-over-year basis.
AVANOS MEDICAL, INC. Price, Consensus and EPS Surprise
AVANOS MEDICAL, INC. price-consensus-eps-surprise-chart | AVANOS MEDICAL, INC. Quote
Margin Analysis
Gross profit came in at $109.7 million, up 9.3% from the prior-year quarter figure. Adjusted gross margin was 60% of net revenues, down 40 bps year over year.
Research and development expenses totaled $8.4 million, down 20.8% year over year. Selling, general and administrative expenses amounted to $103.6 million, up 17.9%.
Adjusted operating profit in the fourth quarter was $26 million, up 30% driven by higher sales volumes. The company reported operating loss of $3.2 million in the quarter under review compared with the year-ago quarter’s operating loss of $8.3 million.
Financial Update
As of Dec 31, 2019, cash and cash equivalents totaled $205.3 million.
Net cash from operating activities for the three months ended Dec 31, 2019, amounted to ($2.9) million, narrower than ($7.4 million) in the prior-year quarter.
Guidance
Avanos expects 2020 revenue growth between 5% and 7% compared to 2019. The Zacks Consensus Estimate for the same is pegged at $737.6 million.
Adjusted EPS is expected between a penny and $1.20. The Zacks Consensus Estimate stands at $1.18.
The company expects lower foreign currency impact in 2020 in comparison to 2019.
Summing Up
Avanos exited the fourth quarter on a strong note. The company continues to gain from core segments — Chronic Care and Pain Management. The recent FDA approval for the new 80-Watt COOLIEF Radiofrequency System buoys optimism. Also, the company completed the Endoclear LLC buyout and also entered into an operating partnership with DHL Supply Chain to enhance Avanos’ network achieve greater productivity and maximize warehouse storage utilization.
However, the contraction in gross margin is worrisome. Moreover, being a pure-play MedTech company, it faces stiff competition from other industry players.
Earnings of Other MedTech Majors at a Glance
Some better-ranked companies, which reported solid results this earnings season, include Stryker Corporation (SYK - Free Report) , Accuray Incorporated (ARAY - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker reported fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the consensus mark by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>